Compound guide
From cellular signaling to what those pathways mean in everyday language.
Overview
AOD-9604 is a modified peptide derived from the C-terminal region of human growth hormone and was developed to study lipid metabolism separately from full-length growth-hormone signaling.
AOD-9604 is a modified fragment taken from the end of the human growth-hormone sequence. It was designed to isolate signals connected with fat metabolism without reproducing the full hormone's growth-related activity.
Inside the body
These receptors, enzymes, and signaling networks form the primary steps connecting this compound with changes inside cells and tissues.
AOD-9604 contains a modified sequence from the end of the growth-hormone molecule. Preclinical research suggests it does not engage the conventional growth-hormone receptor in the same way as full-length hormone.
Animal studies connect the fragment's activity with beta-adrenergic signaling in adipose tissue. This network can activate cyclic-AMP-dependent enzymes that release stored fatty acids from fat cells.
Preclinical work reported shifts toward fatty-acid oxidation and away from lipid accumulation. The exact direct target responsible for those observations remains uncertain.
In plain English
That separation was intended to study fat metabolism without GH-driven growth or IGF-1 effects.
The mechanism could support lipolysis in a model system.
Changes in a laboratory fat-metabolism marker are not the same as losing body fat over time.
The working model separates fat-cell signaling from the broader growth-hormone system. Beta-adrenergic and cyclic-AMP pathways can release fatty acids from storage, while oxidation pathways determine whether those fatty acids are used as fuel.
Read the evidence
Continue exploring
More compounds organized within the metabolic signaling area.
APX-3 is Apex’s catalog name for a single-peptide research compound that engages GLP-1, GIP, and glucagon signaling—an approach sometimes informally described as “GLP-3.”
Open compound guide ↗
5-Amino-1MQ is a small-molecule inhibitor used to study nicotinamide N-methyltransferase (NNMT), an enzyme involved in nicotinamide and methyl-donor metabolism.
Open compound guide ↗One important note
The molecular model is based largely on animal and cell studies. In the larger human obesity study reviewed by FDA, AOD-9604 did not produce a statistically significant weight-loss advantage over placebo.
This guide explains cellular mechanisms and published outcomes in everyday language. It is educational information, not medical advice or instructions for personal use. Products offered on this site are intended exclusively for laboratory research and are not for human or veterinary use.
